Skip to content

Safety and Efficacy of Oral Colostrum Derived Anti Influenza Antibodies in Healthy Volunteers

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01026350
Enrollment
10
Registered
2009-12-04
Start date
2010-01-31
Completion date
Unknown
Last updated
2009-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

modulating immune response to flu antigen

Brief summary

Administration of colostrum enriched with anti-Flu antibodies may alter host's response to the flu virus.

Interventions

DIETARY_SUPPLEMENTcolostrum enriched with anti flu antibodies

each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male volunteers ages 18-60 * If participating in sexual activity that could lead to pregnancy, the study volunteer must agree that two reliable methods of contraception will be used simultaneously while receiving the protocol-specified medication and for 1 month after stopping the medication * Men \> 18 years. * Ability and willingness of subject to provide informed consent * Screening tests' results within 15% of normal values

Exclusion criteria

* Female * Continuous use of the following medications for more than 3 days within 30 days of study entry: * Immunosuppressives * Immune modulators * Systemic glucocorticoids * Anti-neoplastic agents * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry. * Subjects with a clinically significant infectious, immune mediated or malignant disease * Subjects with anemia (Hb \<10.5 gm/dl) * Subjects with thrombocytopenia (platelets \<100K/µl) * Subjects with lymphopenia (absolute lymphocyte count \<0.7) * Subjects who were previously vaccinated against flu. * Subject who received any vaccination within the last 6 months

Design outcomes

Primary

MeasureTime frame
alterations in immune response to flu antigenduring and after administration of colostrum enriched with anti flu antibodies

Countries

Israel

Contacts

Primary Contacttomer adar, MD
tomerad@hadassah.org.il972-2-6778511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026